[{"AccountsPayableCurrent_0_Q1_USD":1609000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":687000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q1_USD":48690000.0,"OtherLiabilitiesCurrent_0_Q1_USD":1993000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_1_Q1_USD":22200000.0,"AccountsAndOtherReceivablesNetCurrent_0_Q1_USD":1108000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q1_USD":1.23,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-22000.0,"OtherLiabilities_0_Q1_USD":17756000.0,"StockIssuedDuringPeriodValueOther_1_Q1_USD":1614000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q1_USD":-12625000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":1165000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-12647000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":1107029000.0,"OtherAssetsNoncurrent_0_Q1_USD":41000.0,"DeferredTaxLiabilities_0_Q1_USD":3007000.0,"BusinessCombinationContingentConsiderationLiability_0_Q1_USD":12719000.0,"InterestReceivable_0_Q1_USD":200000.0,"IncreaseDecreaseInAccountsAndOtherReceivables_1_Q1_USD":93000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":15763000.0,"MarketableSecuritiesCurrent_0_Q1_USD":30998000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":63000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1_Q1_USD":0.0,"ProceedsFromStockPlans_1_Q1_USD":24000.0,"OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_0_Q1_USD":0.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":3739000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":2106000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":1682000.0,"InvestmentsAndCash_0_Q1_USD":53700000.0,"IndefiniteLivedIntangibleAssetsExcludingGoodwill_0_Q1_USD":48700000.0,"InterestAndOtherIncome_1_Q1_USD":242000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q1_USD":100000.0,"ConstructionInProgressExpendituresIncurredButNotYetPaid_1_Q1_USD":462000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":11492000.0,"BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0_Q1_USD":127500000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_1_Q1_USD":-234000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":15000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":16000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q1_USD":30997000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":686000.0,"ContractWithCustomerLiability_0_Q1_USD":199000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":2728000.0,"IncreaseDecreaseInOtherOperatingLiabilities_1_Q1_USD":-768000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1_Q1_pure":0.006,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":21965000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":1637000.0,"LiabilitiesCurrent_0_Q1_USD":10932000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":112504000.0,"Liabilities_0_Q1_USD":28801000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":-206000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":3666000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.73,"CostsAndExpenses_1_Q1_USD":15595000.0,"CommonStockValue_0_Q1_USD":18000.0,"CommonStockSharesOutstanding_0_Q1_shares":17730802.0,"CommonStockSharesIssued_0_Q1_shares":17730802.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":22724000.0,"AssetsCurrent_0_Q1_USD":55918000.0,"Assets_0_Q1_USD":112504000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":1659251.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":2597000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-12110000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":235000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":1088000.0,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":1613000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q1_pure":0.91,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q1_pure":0.0,"ShareBasedCompensation_1_Q1_USD":687000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":11695000.0,"PreferredStockValue_0_Q1_USD":null,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PreferredStockSharesAuthorized_0_Q1_shares":3000000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":-853000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.01,"CommonStockSharesAuthorized_0_Q1_shares":297000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"CommitmentsAndContingencies_0_Q1_USD":null,"AccruedLiabilitiesCurrent_0_Q1_USD":5648000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":17406000.0,"StockholdersEquity_0_Q1_USD":83703000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1025941000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":4116000.0,"OperatingIncomeLoss_1_Q1_USD":-12867000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q1_USD":24000.0,"Ticker":"CLDX","CIK":"744218","name":"CELLDEX THERAPEUTICS, INC.","OfficialName":"Celldex Therapeutics Inc.","form":"10-Q","period":"20200331","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1601609341.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20200506"}]